PFPeptide File
Live Updates
NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·NEWRetatrutide Phase III results — 28.7% body weight reduction confirmed at 12mg/68 weeks·UPDATECJC-1295 half-life study published in Journal of Endocrinology·TRIALBPC-157 human trial enrolment opens Q3 2026·FDARetatrutide NDA submission expected late 2026·RESEARCHNew GLP-1/GIP dual agonist data vs tirzepatide head-to-head·
Compare

Compound Comparisons

Side-by-side evidence comparisons across the peptide and GLP-1 landscape — mechanism, efficacy, tolerability, and trial data in one place.

GLP-1 / Triple Agonist

Retatrutide vs Semaglutide vs Tirzepatide

The three-way data comparison — efficacy, weight loss, tolerability, and mechanism across all three major GLP-1 class drugs.

Strong
Coming Soon

Fat Loss

Best Peptide for Fat Loss 2026

A ranked, evidence-weighted comparison of every compound with meaningful fat-loss data — from AOD-9604 to retatrutide.

Moderate
Coming Soon

Recovery

BPC-157 vs TB-500 vs Thymosin

The three most commonly stacked recovery peptides reviewed head-to-head on mechanism, evidence, and real-world use patterns.

Moderate
Coming Soon

Metabolic

Peptides vs Prescription GLP-1s

Research-grade peptides against FDA-approved GLP-1 drugs — how do they compare on evidence quality, safety, and access?

Moderate
Coming Soon

GLP-1

Compounded vs Brand Semaglutide

What the evidence actually says about compounded semaglutide — bioequivalence, quality control, and regulatory status.

Strong
Coming Soon

More comparisons coming soon

Looking for a specific comparison?

Email us and we'll prioritise it for the next file.

Request a Comparison